Aaron Kantoff, Partner, has significant early and late-stage biotech experience, as well as a background in financial analysis and restructuring. Since joining ATP in 2011, he has been instrumental in helping to create the current investment strategy for the therapeutics team and has been involved with investing in and building many of the portfolio companies.
Prior to joining ATP in 2011, Aaron was a partner at Recess Global, LLC, an investment company, focused on funding startups. Prior to starting Recess, Aaron was a member of the investment banking team at Rothschild Inc., in the Restructuring Group. Selected transactions at Rothschild Inc. include: advising the U.S Treasury on restructuring of Chrysler Group, LLC; assisting Milacron Inc. with the Section 363 sale of assets; working with Delphi Automotive on its in-court Chapter 11 bankruptcy; developing the Penton Media “Pre-packaged” Chapter 11 filing. In addition to his role with Apple Tree, Aaron served as Executive Director of Business Development & Corporate Strategy of Braeburn Pharmaceuticals from 2012 to 2014.
Aaron holds a Bachelor of Science in Finance and International Business from the New York University Stern School of Business.